Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 4/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | SNCA | P37840 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315071 | 1.00 | S100A4 (0.49) | S100A4CDC25BPABPC1LRRK2MAOA | |
| SCHEMBL14436926 | 0.99 | S100A4 (0.50) | S100A4CDC25BPABPC1LRRK2MAOA | |
| SCHEMBL1314052 | 0.97 | S100A4 (0.49) | S100A4CDC25BPABPC1LRRK2MAOA | |
| SCHEMBL1314054 | 0.97 | S100A4 (0.49) | S100A4CDC25BPABPC1LRRK2MAOA | |
| SCHEMBL1315671 | 0.97 | S100A4 (0.49) | S100A4CDC25BPABPC1LRRK2MAOA | |
| SCHEMBL1315670 | 0.97 | S100A4 (0.49) | S100A4CDC25BPABPC1LRRK2MAOA | |
| SCHEMBL14447700 | 0.81 | S100A4 (0.54) | S100A4CDC25BMAPTTDP1ALDH1A1 | |
| SCHEMBL29462445 | 0.79 | PABPC1 (0.55) | CDC25BPABPC1LRRK2MAOAMAOB | |
| SCHEMBL1898632 | 0.79 | PABPC1 (0.55) | CDC25BPABPC1LRRK2MAOAMAOB | |
| SCHEMBL574049 | 0.79 | PABPC1 (0.55) | CDC25BPABPC1LRRK2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267836-A1 | Process For Preparing Ethylenedialkylphosphinic Acids, Esters And Salts And Use Thereof | CLARIANT PLASTICS & COATINGS LTD (CH) | 2017-09-21 | — | — | US | disclosed |
| US-9279085-B2 | Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2016-03-08 | — | — | US | disclosed |
| US-9181487-B2 | Process for preparing ethylenedialkylphosphinic acids, esters and salts by means of acetylene and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-11-10 | — | — | US | disclosed |
| US-9139714-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols-acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-09-22 | — | — | US | disclosed |
| US-9085734-B2 | Process for preparing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts by means of alkylene oxides and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-07-21 | — | — | US | disclosed |
| US-9068119-B2 | Method for producing mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carobxylic acid and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-06-30 | — | — | US | disclosed |
| US-9035088-B2 | Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-19 | — | — | US | disclosed |
| US-9018413-B2 | Method for the production of alkylphosphonic acids, esters, and salts by oxidizing alkylphosphonous acids, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-04-28 | — | — | US | disclosed |
| US-8987490-B2 | Method for the production of monohydroxy-functionalized dialkylphosphinic acids, esters, and salts using ethylene oxide, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | disclosed |
| US-8987489-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ether and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | disclosed |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | disclosed |
| US-20100303119-A1 | Microfluidic Lasers | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100190901-A1 | Alkylphosphonous Acids, Salts and Esters, Methods for the Production Thereof, and Use of the Same | CLARIANT FINANCE (BVI) LIMITED (VG) | 2010-07-29 | — | — | US | disclosed |
| US-20100181284-A1 | METHOD OF OBTAINING ELECTRONIC CIRCUITRY FEATURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100075848-A1 | Laser Imaging | DATALASE LTD. (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100009173-A1 | COMPOSITIONS AND METHODS FOR CREATING ELECTRONIC CIRCUITRY | E. I. DU PONTE DE NEMOURS AND COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090017309-A1 | COMPOSITIONS AND METHODS FOR CREATING ELECTRONIC CIRCUITRY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1704057-A1 | LASER IMAGING | Sherwood Technology LTD. (GB) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006086551-A2 | MICROFLUIDIC LASERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005068207-A1 | LASER IMAGING | DATALASE LTD. (GB) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267836-A1 | Process For Preparing Ethylenedialkylphosphinic Acids, Esters And Salts And Use Thereof | ENPP1, ENPP3, FADS2 | S100A4 2006/4885CDC25B 1141/4885PABPC1 1374/4885 |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | AOC3, SCO2, AOC2 | S100A4 4517/4885CDC25B 1477/4885PABPC1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.